Major Depressive Disorder, Single Episode, Unspecified Clinical Trial
— SMADSOfficial title:
Self-Management Support in Primary Care
Verified date | February 2018 |
Source | Universitätsklinikum Hamburg-Eppendorf |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Anxiety, Depression and Somatoform disorders are highly prevalent in primary care. Very often
these conditions remain undiscovered and/or untreated.
In order to ease this urgent health care problem in the future, the investigators conduct a
cluster-randomized controlled trial, implementing a tandem working cooperation between a
nurse practitioner (Counseling Assistant - CA) and a general practitioner (GP) on-site its
own practise.
The CA's task is to enhance the patients abilities to engage in a better self-management of
their psychological symptoms and complaints, to enhance self-efficacy and empower the
patients to tackle problems of daily living.
Status | Completed |
Enrollment | 364 |
Est. completion date | September 2015 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients scoring >= 5 on the Patient Health Questionnaire (German Version), corresponding to a probable or established diagnosis of Anxiety, Depression or Somatoform Disorder Exclusion Criteria: - Negation of Inclusion Criteria |
Country | Name | City | State |
---|---|---|---|
Germany | Primary Care Practices | Hamburg |
Lead Sponsor | Collaborator |
---|---|
Universitätsklinikum Hamburg-Eppendorf | German Federal Ministry of Education and Research |
Germany,
Grochtdreis T, Zimmermann T, Puschmann E, Porzelt S, Dams J, Scherer M, König HH. Cost-utility of collaborative nurse-led self-management support for primary care patients with anxiety, depressive or somatic symptoms: A cluster-randomized controlled trial — View Citation
Porzelt S, Zimmermann T, Ernst A, Puschmann E, Scherer M. Wie Pflegekräfte in der hausärztlichen Versorgung Patienten mit psychischen Beschwerden gezielt unterstützen können. Pflegewissenschaft, 18(7-8): 355-361, 2016.
Zimmermann T, Puschmann E, Bäter G, Carstens S, Scherer M. Selbstmanagement stärken bei psychosozialen Belastungen. Die Kerbe - Forum für soziale Psychiatrie 4, 24-26, 2012.
Zimmermann T, Puschmann E, Ebersbach M, Daubmann A, Steinmann S, Scherer M. Effectiveness of a primary care based complex intervention to promote self-management in patients presenting psychiatric symptoms: study protocol of a cluster-randomized controlled trial. BMC Psychiatry. 2014 Jan 3;14:2. doi: 10.1186/1471-244X-14-2. — View Citation
Zimmermann T, Puschmann E, Porzelt S, Ebersbach M, Ernst A, Thomsen P, Scherer M. [Promoting Self-Management in Primary Care - the Association of Motivation for Change, Self-Efficacy and Psychological Distress Prior to the Onset of Intervention]. Psychiat — View Citation
Zimmermann T, Puschmann E, Porzelt S, Ebersbach M, Ernst A, Thomsen T, Scherer M. Selbstmanagementfo¨rderung in der ambulanten Versorgung. Programm einer niedrigschwelligen, komplexen, psychosozialen Intervention durch Pflegekra¨fte in der Hausarztpraxis. Zeitschrift für Allgemeinmedizin, 91, 11, 456-462, 2015.
Zimmermann T, Puschmann E, van den Bussche H, Wiese B, Ernst A, Porzelt S, Daubmann A, Scherer M. Collaborative nurse-led self-management support for primary care patients with anxiety, depressive or somatic symptoms: Cluster-randomised controlled trial ( — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Coping with Illness scale | Assesses a broad range of cognitive, behavioral and emotional aspects of coping with illness. Investigators use the short version (FKV-LIS) | Baseline, 8 Weeks, 12 Months | |
Primary | General Self-Efficacy Scale (GSE) | GSE assesses a general sense of perceived self-efficacy. It predicts coping with daily hassles as well as adaptation after experiencing all kinds of stressful life events. http://userpage.fu-berlin.de/%7Ehealth/engscal.htm "The construct of Perceived Self-Efficacy reflects an optimistic self-belief (Schwarzer, 1992). This is the belief that one can perform a novel or difficult tasks, or cope with adversity -- in various domains of human functioning. Perceived self-efficacy facilitates goal-setting, effort investment, persistence in face of barriers and recovery from setbacks. It can be regarded as a positive resistance resource factor. Ten items are designed to tap this construct. Each item refers to successful coping and implies an internal-stable attribution of success. Perceived self-efficacy is an operative construct, i.e., it is related to subsequent behavior and, therefore, is relevant for clinical practice and behavior change." |
Baseline, 8 Weeks, 12 Months | |
Secondary | Change in Symptom Score Patient's Health Questionnaire (German Version) | Reducing the symptoms score in the "Patient's Health Questionnaire (German Version)". Reducing symptom score per scale -2,5 units comparing group mean of the intervention group and the group mean of the control group, power 80%, probability 0,05. Effect size d=0,5. | Baseline, 8 Weeks, 12 Months | |
Secondary | Health Related Quality of Life | Enhancing the health related quality of life in the patients using EQ-5D http://www.euroqol.org/ EQ-5D (European-Quality-of-Life-5-Dimensions): "Descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of three responses. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension." |
Baseline, 8 Weeks, 12 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02078258 -
Attention Bias Modification Treatment for Major Depressive Disorder in Adolescents
|
N/A | |
Completed |
NCT01894815 -
Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
|
Phase 3 | |
Completed |
NCT01361815 -
Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)
|
N/A |